TNXB Antibody

What is TNXB and why is it important in research?

TNXB (tenascin XB) is a large extracellular matrix glycoprotein with a canonical length of 4244 amino acid residues and a molecular mass of approximately 458.4 kDa in humans. This protein belongs to the tenascin family and plays crucial roles in cytoskeleton organization and cell adhesion . TNXB is highly expressed in fetal tissues including adrenal glands, testis, and various muscle types (smooth, striated, and cardiac) . Its importance in research stems from its involvement in various physiological and pathological processes, including connective tissue disorders and cartilage homeostasis .

What are the most common applications for TNXB antibodies?

TNXB antibodies are versatile research tools employed in multiple experimental techniques. The most commonly utilized applications include:

• Immunohistochemistry (IHC): Widely used for detecting TNXB in tissue sections, particularly in formalin-fixed, paraffin-embedded samples

• Western Blot (WB): Used to detect and quantify TNXB protein expression in cell or tissue lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): Employed for quantitative analysis of TNXB in solution

• Immunocytochemistry (ICC) and Immunofluorescence (IF): Used to visualize TNXB localization in cells

• Flow Cytometry (FCM): Applied to detect TNXB in cell populations

Each application offers distinct advantages depending on the research question being addressed.

What is the normal tissue distribution of TNXB protein?

TNXB shows a specific expression pattern in human tissues. It is predominantly expressed in:

• Fetal adrenal gland

• Fetal testis

• Fetal smooth, striated, and cardiac muscle

• Adult connective tissues, particularly in the extracellular matrix

This distribution pattern is important when selecting positive control tissues for antibody validation and when interpreting experimental results. The protein's subcellular localization is primarily in the extracellular matrix, and it is secreted rather than membrane-bound or cytoplasmic .

What are the known isoforms of TNXB?

Up to four different isoforms of TNXB have been reported in humans . These isoforms result from alternative splicing of the TNXB gene. When selecting or validating an anti-TNXB antibody, it's crucial to understand which epitopes and isoforms the antibody recognizes. This knowledge helps ensure accurate interpretation of results, particularly when comparing findings across different studies that may have used antibodies targeting different TNXB regions.

How does TNXB expression differ in pathological conditions?

Recent research has revealed significant variations in TNXB expression between normal and pathological states. In hemophilic arthropathy (HA), TNXB shows lower expression levels compared to osteoarthritis (OA) cartilage, as demonstrated by immunohistochemistry . Similarly, studies suggest that TNXB mRNA and protein are lost in murine pancreatic tumors, which contrasts with increased expression of another tenascin family member, Tenascin-C (TNC) .

These differential expression patterns make TNXB a potentially valuable biomarker for certain disease states and highlight the importance of carefully validated antibodies for accurate assessment of TNXB levels in various pathological conditions.

What are the epigenetic mechanisms regulating TNXB expression?

Genome-wide DNA methylation analysis has revealed that TNXB exhibits significant methylation differences between hemophilic arthritis and osteoarthritis . This aberrant methylation appears to correlate with reduced TNXB expression in affected tissues. Researchers investigating TNXB should consider these epigenetic mechanisms when designing experiments, as they may influence antibody-based detection methods.

When studying conditions with altered TNXB levels, complementary approaches such as methylation-specific PCR or bisulfite sequencing alongside antibody-based protein detection can provide more comprehensive insights into the regulatory mechanisms affecting TNXB expression.

How does TNXB knockdown affect cellular and tissue function?

Experimental knockdown of TNXB through techniques such as siRNA delivery has demonstrated several significant biological effects:

• Promotion of chondrocyte apoptosis

• Induction of cartilage degradation

• Contribution to subchondral bone loss

• Alteration of extracellular matrix homeostasis

These functional consequences of TNXB reduction appear to be mediated at least partially through modulation of AKT phosphorylation, as indicated by KEGG enrichment analysis and Western blot studies . This mechanistic insight provides important context for researchers designing interventional studies targeting TNXB or its downstream pathways.

What signaling pathways interact with TNXB?

TNXB interacts with several key signaling pathways, most notably the AKT pathway. Research indicates that TNXB knockdown affects AKT phosphorylation, and treatment with AKT agonists such as SC79 can partially rescue the cellular changes induced by TNXB depletion . This relationship suggests that TNXB may regulate extracellular matrix homeostasis and cell survival through modulation of AKT signaling.

When conducting studies involving TNXB antibodies, researchers should consider examining these interconnected pathways to gain a more comprehensive understanding of TNXB's biological roles and regulatory mechanisms.

What are the key factors in selecting an appropriate anti-TNXB antibody?

Selecting the optimal anti-TNXB antibody requires careful consideration of several factors:

• Antibody type: Polyclonal versus monoclonal antibodies offer different advantages. Polyclonal antibodies recognize multiple epitopes and may provide stronger signals, while monoclonal antibodies offer higher specificity for a single epitope.

• Species reactivity: Ensure the antibody recognizes TNXB from your species of interest. Available antibodies show reactivity to human, mouse, and rat TNXB, among others .

• Application suitability: Verify that the antibody has been validated for your specific application (WB, IHC, IF, etc.).

• Epitope location: Consider which region of TNXB the antibody recognizes, especially if studying specific isoforms or post-translationally modified variants.

• Validation data: Review available validation data, including positive and negative controls, to ensure antibody specificity and sensitivity.

How should researchers validate TNXB antibodies for specific applications?

Proper validation of TNXB antibodies is essential for reliable research outcomes:

• Positive and negative controls: Include tissues or cells known to express or lack TNXB. Fetal adrenal, testis, and muscle tissues serve as good positive controls .

• Knockdown/knockout validation: Compare antibody signals between wild-type samples and those with TNXB knockdown or knockout to confirm specificity.

• Cross-reactivity testing: Assess potential cross-reactivity with other tenascin family members, particularly Tenascin-C, which may be upregulated in conditions where TNXB is downregulated .

• Multiple antibody comparison: When possible, compare results using antibodies targeting different TNXB epitopes to enhance confidence in findings.

• Complementary techniques: Validate protein-level findings with mRNA detection methods like qPCR or RNA-seq.

What optimization strategies are recommended for TNXB immunohistochemistry?

Optimizing IHC protocols for TNXB detection requires attention to several parameters:

• Antigen retrieval: Given TNXB's large size and extensive glycosylation, optimal antigen retrieval methods may differ from standard protocols. Test both heat-induced epitope retrieval (HIER) and enzymatic methods to determine which best exposes TNXB epitopes in your tissue type.

• Antibody dilution: Titrate antibody concentrations to determine the optimal dilution that maximizes specific signal while minimizing background.

• Incubation conditions: Test different incubation times and temperatures, as TNXB's extracellular matrix localization may require longer antibody penetration times.

• Detection systems: Compare different detection methods (e.g., DAB chromogen versus fluorescent secondary antibodies) to determine which provides the best signal-to-noise ratio for your specific tissues.

• Counterstaining: Select appropriate counterstains that don't obscure TNXB staining patterns, particularly in extracellular matrix regions.

How can researchers troubleshoot common issues with TNXB Western blotting?

Western blot detection of TNXB presents specific challenges due to its large molecular weight (458.4 kDa) and post-translational modifications:

• Sample preparation: Use buffer systems that effectively solubilize extracellular matrix proteins. Consider including specific protease inhibitors to prevent degradation.

• Gel selection: Utilize low percentage gels (3-6%) or gradient gels that can effectively resolve high molecular weight proteins.

• Transfer conditions: Implement extended transfer times or specialized transfer systems designed for large proteins. Consider wet transfer methods rather than semi-dry for proteins >300 kDa.

• Blocking optimization: Test different blocking agents (BSA vs. non-fat milk) as some may interfere with antibody binding to glycosylated proteins like TNXB.

• Signal amplification: For low-abundance samples, consider using signal amplification systems to enhance detection sensitivity.

What role does TNXB play in cartilage-related pathologies?

Recent research has identified important connections between TNXB and cartilage homeostasis. In hemophilic arthropathy, TNXB levels are significantly reduced compared to other arthritic conditions like osteoarthritis . Experimental knockdown of TNXB induces cartilage degradation and promotes chondrocyte apoptosis, suggesting a protective role for TNXB in maintaining cartilage integrity .

These findings open new research avenues exploring TNXB as a potential therapeutic target in arthropathies. Researchers investigating these possibilities should employ validated TNXB antibodies for accurate assessment of baseline expression and intervention outcomes.

How can TNXB antibodies be used in therapeutic development research?

TNXB antibodies serve as valuable tools in developing and evaluating potential therapeutics:

• Target validation: Confirm TNXB involvement in disease processes through immunohistochemistry and protein quantification in relevant tissues.

• Therapeutic monitoring: Measure changes in TNXB levels or localization in response to experimental treatments.

• Mechanism elucidation: Use phospho-specific antibodies to monitor effects on TNXB-related signaling pathways, such as AKT phosphorylation .

• Biomarker development: Evaluate TNXB as a potential diagnostic or prognostic biomarker for conditions with altered TNXB expression.

When pursuing these applications, researchers should select antibodies with demonstrated specificity and sensitivity for the particular experimental system being used.